Article references (20 references )

  1. Souadjian JV, Enriquez P, Silverstein MN et al. The spectrum of diseases associated with thymoma: coincidence or syndrome? Arch Intern Med. 1974;134(2):374-9. PubMed | Google Scholar

  2. Venuta F, Anile M, Diso D et al. Thymoma and thymic carcinoma. Eur J Cardiothorac Surg. 2010;37(1):13-25. PubMed | Google Scholar

  3. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77(5):1860-9. PubMed | Google Scholar

  4. Cheney RT. The biologic spectrum of thymic epithelial neoplasms: current status and future prospects. J Natl Compr Canc Netw. 2010;8(11):1322-8. PubMed | Google Scholar

  5. Romi F, Skeie GO, Aarli JA et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol. 2000;247(5):369-75. PubMed | Google Scholar

  6. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer. 2004;4(1):36-44. PubMed | Google Scholar

  7. Romi F, Bř L, Skeie GO et al. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 2002;128(1):82-9. PubMed | Google Scholar

  8. Skeie GO, Bentsen PT, Freiburg A et al. Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells. Scand J Immunol. 1998;47(1):76-81. PubMed | Google Scholar

  9. Romi F, Skeie GO, Gilhus NE et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. 2005;62(3):442-6. PubMed | Google Scholar

  10. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171-83. PubMed | Google Scholar

  11. Chuang W-Y, Ströbel P, Gold R et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol. 2005;58(4):644-8. PubMed | Google Scholar

  12. Amdahl C, Alseth EH, Gilhus NE et al. Polygenic disease associations in thymomatous myasthenia gravis. Arch Neurol. 2007;64(12):1729-33. PubMed | Google Scholar

  13. Burch J, Warren-Gash C, Ingham V et al. Myasthenia gravis-a rare presentation with tongue atrophy and fasciculation. Age Ageing. 2006;35(1):87-8. PubMed | Google Scholar

  14. Rai B. Myasthenia gravis: challenge to dental profession. Internet J Acad Phys Assist. 2006;6(1):18-20.

  15. Patil PM, Singh G, Patil SP. Dentistry and the myasthenia gravis patient: a review of the current state of the art. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(1):e1-8. PubMed | Google Scholar

  16. Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol. 2014;9(9 Supplement 2):S137-42. PubMed | Google Scholar

  17. Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90-100. PubMed | Google Scholar

  18. Weijnen FG, van der Bilt A, Kuks JB et al. Masticatory performance in patients with myasthenia gravis. Arch Oral Biol. 2002;47(5):393-8. PubMed | Google Scholar

  19. Harnett MT, Chen W, Smith SM. Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness. Neuropharmacology. 2009;57(5):502-5. PubMed | Google Scholar

  20. Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation. Drug Saf. 2011;34(10):839-47. PubMed | Google Scholar